AURA compared with LXEO: revenue, margins and what each company keeps, and the suppliers and customers both name

AURAAura Biosciences, Inc.

Mkt capRevenueRevenue

LXEOLexeo Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

AURAAura Biosciences, Inc.

LXEOLexeo Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

AURAAura Biosciences, Inc.

6.14▼−2.46%· post 6.14

Mkt cap$636.7M

LXEOLexeo Therapeutics, Inc.

3.14▲+2.61%· post 3.14

ClosedOct 30 '26

Mkt cap$257.6M

Compare

ClosedOct 30 '26

AURAAura Biosciences, Inc.

LXEOLexeo Therapeutics, Inc.

6.14▼−2.46%post 6.14

Price

3.14▲+2.61%post 3.14

$636.7M

Mkt cap

$257.6M

AURA6.14▼−2.46%vsLXEO3.14▲+2.61%ClosedOct 30 '26

rebased to 0%

AURA, solidLXEO, dashed

AURA: latest quarter not drawable. LXEO: latest quarter not drawable.Method ›

direct ties · both sidesSources ›

direct ties · both sides

No disclosed counterparties: AURA, LXEO.

Role chip = supplier or customerSource: SEC EDGAR